日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study

DANGER 呕吐研究:每周一次给予奈妥匹坦/帕洛诺司琼联合地塞米松治疗 5 周的同步放化疗的安全性和止吐疗效

Detlefsen, Sofie S; Andersen, Ditte S; Knudsen, Anja Ø; Nøttrup, Trine J; Möller, Sören; Nyvang, Gitte-Bettina; Jørgensen, Trine L; Herrstedt, Jørn; Ruhlmann, Christina H

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

2023年MASCC和ESMO关于预防化疗和放疗引起的恶心和呕吐的指南更新

Herrstedt, J; Clark-Snow, R; Ruhlmann, C H; Molassiotis, A; Olver, I; Rapoport, B L; Aapro, M; Dennis, K; Hesketh, P J; Navari, R M; Schwartzberg, L; Affronti, M L; Garcia-Del-Barrio, M A; Chan, A; Celio, L; Chow, R; Fleury, M; Gralla, R J; Giusti, R; Jahn, F; Iihara, H; Maranzano, E; Radhakrishnan, V; Saito, M; Sayegh, P; Bosnjak, S; Zhang, L; Lee, J; Ostwal, V; Smit, T; Zilic, A; Jordan, K; Scotté, F

Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer

卡铂联合紫杉醇和组蛋白去乙酰化抑制剂伏立诺他治疗复发性铂敏感卵巢癌

Meteran, Hanieh; Knudsen, Anja Ør; Jørgensen, Trine Lembrecht; Nielsen, Dorte; Herrstedt, Jørn

Prevention of Taste Alterations in Patients with Cancer Receiving Paclitaxel- or Oxaliplatin-Based Chemotherapy-A Pilot Trial of Cannabidiol

预防接受紫杉醇或奥沙利铂化疗的癌症患者味觉改变——大麻二酚的初步试验

Dominiak, Helena S H; Hasselsteen, Simone D; Nielsen, Sebastian W; Andersen, Jens Rikardt; Herrstedt, Jørn

Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles

化疗引起的恶心呕吐(CINV)持续时间作为预测后期化疗周期中CINV复发的指标

Navari, Rudolph; Binder, Gary; Molasiotis, Alex; Herrstedt, Jørn; Roeland, Eric J; Ruddy, Kathryn J; LeBlanc, Thomas W; Kloth, Dwight D; Klute, Kelsey A; Papademetriou, Eros; Schmerold, Luke; Schwartzberg, Lee

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents

2023年MASCC/ESMO共识建议更新:预防高致吐风险抗肿瘤药物引起的恶心和呕吐

Herrstedt, Jørn; Celio, L; Hesketh, P J; Zhang, L; Navari, R; Chan, A; Saito, M; Chow, R; Aapro, M

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

2023年MASCC/ESMO共识建议更新:预防多日化疗、大剂量化疗及突破性恶心呕吐后的恶心呕吐

Rapoport, Bernardo Leon; Herrstedt, Jørn; Snow, Rebecca Clark; Radhakrishnan, Venkatraman; Saito, Mitsue; Navari, Rudolph M; Smit, Teresa

Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis

免疫疗法对伴或不伴脑转移的非小细胞肺癌患者的疗效和耐受性

Bjørnhart, Birgitte; Hansen, Karin Holmskov; Asmussen, Jon Thor; Jørgensen, Trine Lembrecht; Herrstedt, Jørn; Schytte, Tine

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes

预防老年患者化疗引起的恶心呕吐:优化治疗效果

Herrstedt, Jørn; Lindberg, Sanne; Petersen, Peter Clausager

Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects

III期ENGOT-OV16/NOVA研究的专项分析:尼拉帕尼治疗伴有同源重组修复缺陷的生殖系BRCA野生型复发性卵巢癌的疗效

Mirza, Mansoor Raza; Lindahl, Gabriel; Mahner, Sven; Redondo, Andrés; Fabbro, Michel; Rimel, Bobbie J; Herrstedt, Jørn; Oza, Amit M; Canzler, Ulrich; Berek, Jonathan S; González-Martín, Antonio; Follana, Phillipe; Lord, Rosemary; Azodi, Masoud; Estenson, Kasey; Wang, Zebin; Li, Yong; Gupta, Divya; Matulonis, Ursula; Feng, Bin